<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586492</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2018-05</org_study_id>
    <nct_id>NCT03586492</nct_id>
  </id_info>
  <brief_title>Coronary Flow Reserve (CFR) in Cardiovascular Risk Stratification</brief_title>
  <acronym>CFR-OR</acronym>
  <official_title>SPECT Myocardial Perfusion Reserve Using a Cadmium Zinc Telluride (CZT) Camera in Cardiovascular Risk Stratification and Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CFR has been studied for few years using 82 Rubidium PET (positron emission tomography) /CT.
      CFR has shown to be correlated with cardiovascular events occurring in the 10 following
      years. CFR also helps to identify multivessel coronary disease. Few studies have shown the
      possibility to calculate CFR during myocardial perfusion SPECT on new ultrafast CZT cameras.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the contribution of CZT SPECT CFR in cardiovascular risk stratification: correlation
      with clinical scores, with calcium score, and when pathological with coronarography findings
      especially fractional flow reserve (FFR).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Anticipated">November 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional and global CFR</measure>
    <time_frame>Day 0</time_frame>
    <description>Regional and global CFR calculated from CZT SPECT myocardial perfusion: correlation with clinical score and calcium score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FFR Regional CFR after one year of medical treatment</measure>
    <time_frame>Up to one year</time_frame>
    <description>FFR measured during coronarography if there is an intermediate stenosis Regional CFR if there is an intermediate coronary stenosis with medical treatment, after one year of treatment, calculated during a new SPECT CZT exam</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ischemia, Myocardial</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Patient with myocardial ischemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CZT SPECT acquisition</intervention_name>
    <description>CZT SPECT acquisition, with dynamic stress and rest acquisitions to calculate CFR If pathological, coronarography with FFR measurement if necessary In case of intermediate coronary stenosis with medical treatment, SPECT CFR evaluation after one year of treatment</description>
    <arm_group_label>Patient with myocardial ischemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients referred for myocardial ischemia screening

        Exclusion Criteria:

          -  Patient already suffering from coronary disease with angioplasty, bypass surgery or
             myocardial infarction.

          -  Contraindications related to the stress test:

        Acute Coronary Syndrome &lt;5 days Unstable angina Stenosis of left main artery untreated
        Uncontrolled severe rhythm disorders Uncontrolled heart failure

          -  Contraindications to dipyridamole and regadenoson:

        Hypotension (systolic &lt;90mmHg) Severe pulmonary arterial hypertension Bradycardia &lt;40 beats
        / minute Sinusal Dysfunction and 2nd or 3rd degree Atrioventricular block Decompensated
        Heart Failure with Ejection Fraction &lt;25% Stenosis of supra-aortic trunks unilateral&gt; 70%
        or bilateral&gt; 50% Dipyridamole and regadenoson allergy

          -  Patients with pacemaker, or who have had valvular surgery,

          -  Well-known dilated cardiopathy

          -  Pregnant or breastfeeding women,

          -  Minor people

          -  Persons under guardianship or under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu BAILLY, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR d'Orléans</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie DESPUJOLS</last_name>
    <phone>+33238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie TATSI TOTOUOM</last_name>
    <phone>+33238744086</phone>
    <email>elodie.tatsi-totouom@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHR d'Orleans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu BAILLY, Dr</last_name>
      <email>matthie.bailly@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maxime COURTEHOUX, Dr</last_name>
      <email>m.courtehoux@chru-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990 Mar 15;15(4):827-32.</citation>
    <PMID>2407762</PMID>
  </reference>
  <reference>
    <citation>Agostini D, Roule V, Nganoa C, Roth N, Baavour R, Parienti JJ, Beygui F, Manrique A. First validation of myocardial flow reserve assessed by dynamic (99m)Tc-sestamibi CZT-SPECT camera: head to head comparison with (15)O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1079-1090. doi: 10.1007/s00259-018-3958-7. Epub 2018 Mar 1.</citation>
    <PMID>29497801</PMID>
  </reference>
  <reference>
    <citation>Assante R, Zampella E, Arumugam P, Acampa W, Imbriaco M, Tout D, Petretta M, Tonge C, Cuocolo A. Quantitative relationship between coronary artery calcium and myocardial blood flow by hybrid rubidium-82 PET/CT imaging in patients with suspected coronary artery disease. J Nucl Cardiol. 2017 Apr;24(2):494-501. doi: 10.1007/s12350-015-0359-1. Epub 2016 Jan 15.</citation>
    <PMID>26780529</PMID>
  </reference>
  <reference>
    <citation>Ben Bouallègue F, Roubille F, Lattuca B, Cung TT, Macia JC, Gervasoni R, Leclercq F, Mariano-Goulart D. SPECT Myocardial Perfusion Reserve in Patients with Multivessel Coronary Disease: Correlation with Angiographic Findings and Invasive Fractional Flow Reserve Measurements. J Nucl Med. 2015 Nov;56(11):1712-7. doi: 10.2967/jnumed.114.143164. Epub 2015 Sep 3.</citation>
    <PMID>26338893</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CFR</keyword>
  <keyword>SPECT</keyword>
  <keyword>CZT</keyword>
  <keyword>Coronary</keyword>
  <keyword>Calcium score</keyword>
  <keyword>Scintigraphy</keyword>
  <keyword>Myocardial perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

